This year’s fair competition among statin/ezetimibe complexes
Fierce competition is expected among complex drugs owning the strong function of inhibiting cholesterol with the combination of statin and ezetimibe.
In particular, the three-way fight – Chong Kun Dang which acquired the sale right of the selected drug, ‘Vytorin,’ Daewoong Pharmaceutical that re...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
